SFRP4 As A Novel Diagnostic And Therapeutic Target For Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Gastric cancer is a common cancer with poor survival, but is and potentially curable when diagnosed at an early stage. However currently there are no non-invasive markers for the early detection of gastric cancer, and treatments for advanced cancer are limited. Secreted frizzled related protein 4 (SFRP4) is a protein that is thought to play a role in invasion of gastric cancer. This study will investigate the utility SFRP4 as a diagnostic test and possible therapeutic for gastric cancer.
Molecular Characterisation Of Serous Ovarian Cancer With Poor Clinical Outcome
Funder
National Health and Medical Research Council
Funding Amount
$532,136.00
Summary
Ovarian cancer is the 5th most common cancer in women, and most lethal gynaecologic malignancy. Despite aggressive surgery and multi-drug chemotherapy the majority of women experience recurrence and ~70% will succumb to the disease. This project will investigate two molecular subtypes of ovarian cancer previously identified by our laboratory to better understand mechanisms associated with poor treatment response.
Characterising The Tumour Suppressive Function Of Myoepithelial Cell Stefin A In Ductal Carcinoma In Situ
Funder
National Health and Medical Research Council
Funding Amount
$474,840.00
Summary
Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer, whereby the tumour cells remain restrained by myoepithelial cells that surround breast ducts. Predicting which cases of DCIS will later develop invasive cancer is difficult, meaning that the majority of patients have treatment. Stefin A is a protease inhibitor in myoepithelial cells shown to block cancer invasion and we aim to test the function of this protein in DCIS and its potential as a prognostic marker.
Use Of Circulating Tumour DNA To Characterise The Mutational Landscape Of Marginal Zone Lymphoma, Monitor Treatment Response And Detect Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.
Characterisation Of A Novel PI3-kinase Signal Terminating Enzyme In Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$633,512.00
Summary
Breast cancer is the most common malignancy among females, affecting 1 in 9 women before the age of 85. Normally cells divide only when they receive a stimulus from a hormone or growth factor. The PI3K pathway which responds to these stimuli has been implicated in cancer where cells divide uncontrollably and invade surrounding tissue. We have identified a potential cancer suppressing gene, PIPP, which turns off PI3K growth signals. We aim to characterize the role of PIPP in breast cancer.
Molecular Characterisation Of Telomere Trimming And Its Role In Cell Proliferative Capacity
Funder
National Health and Medical Research Council
Funding Amount
$403,439.00
Summary
Telomeres are protective structures at the ends of chromosomes. Telomere length is a major determinant of how many times a cell can proliferate. We have recently discovered a rapid telomere shortening process that we have called telomere trimming. We will analyse the molecular details of this process to determine whether it could be used to shorten telomeres and stop cancer cell proliferation, and whether blocking it could increase cell proliferation in patients with short telomere syndromes.
Using MiR-200 To Find New Therapeutic Targets For Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$563,152.00
Summary
Neuroblastoma is one of the most common cancers in children. We have found that a genetic regulator, called microRNA, can limit the ability of neuroblastoma cells to invade surrounding tissues and metastasise. We aim use the microRNAs to find new therapeutic targets that may work in combination with existing treatments, reducing the short term toxicity and long term deleterious effects of current treatments.
Interaction Of TRF2 With DNA Repair Proteins In Alternative Lengthening Of Telomeres
Funder
National Health and Medical Research Council
Funding Amount
$297,246.00
Summary
10-15% of human cancers, including some of the most difficult-to-treat and aggressive, depend for their continuing growth on a molecular process called Alternative Lengthening of Telomeres (ALT). We have identified for the first time a protein whose normal role includes repressing ALT. We will study how this protein works, what its molecular partners are, and how these molecules interact with each other. This information is expected to lay the foundations for cancer treatments that target ALT.